Contact Us
We're here from 9 am to 8 pm ET.
800.963.1778
LUCENTIS 0.5 mg prefilled syringe
On the go?
Download and print the
Prefilled syringe
roadmap
.

EFFICACY DELIVERED

LUCENTIS® (ranibizumab injection) 0.5 mg prefilled syringe

The Efficacy and Safety of LUCENTIS is now prefilled.

LUCENTIS 0.5 mg is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO) and myopic choroidal neovascularization (mCNV).

Contact your Franchise Program Manager to learn about updates to our purchasing programs for the LUCENTIS 0.5 mg prefilled syringe.

Committed to helping you and your patients access LUCENTIS 0.5 mg prefilled syringe

Clinical
Specialist

Field
Reimbursement
Manager

Franchise
Program Manager

Contact now

IMPORTANT SAFETY INFORMATION

LUCENTIS is contraindicated in patients with ocular or periocular infections or hypersensitivity to ranibizumab or any of the excipients in LUCENTIS.

Intravitreal injections, including those with LUCENTIS, have been associated with endophthalmitis, retinal detachment, and iatrogenic traumatic cataract.

Increases in intraocular pressure have been noted both preinjection and post-injection with LUCENTIS.

Although there was a low rate of arterial thromboembolic events (ATEs) observed in the LUCENTIS clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarcation, or vascular death (including deaths of unknown cause).

In the LUCENTIS Phase III clinical trials, the most common ocular side effects included conjunctival hemorrhage, eye pain, vitreous floaters, and increased intraocular pressure. The most common non-ocular side effects included nasopharyngitis, anemia, nausea, and cough.

For additional safety information, please see LUCENTIS full prescribing information.